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lines on Axillary Node Clearance (ANC) in patients with early and localised
primary breast cancer. A 2015 ABS Consensus statement explores how ANC
may be avoided. There is controversy in the management of patients with
low burden axillary disease as predicted from the Ultrasound (US) Scan.
Aim: To investigate the efﬁcacy of the US scan in identifying low burden
axillary disease in patients with primary breast cancer.
Method: A retrospective study was performed at a symptomatic breast
unit including all patients undergoing an ANC between January and
December 2014.
Result: A total of 112 patients had an ANC. All patients had an US Axilla.
72% had light burden disease on US scan (<3 nodes). 27 of these had 3 or
more positive nodes on ANC.
Conclusion: The majority of low burden disease identiﬁed from US scan
had a positive ANC. This suggests in symptomatic breast cancer that low
burden disease cannot always be predicted. Our current axillary man-
agement will be unchanged and we plan to conduct a prospective trial
having asked the radiologists to comment speciﬁcally on number of
involved nodes.http://dx.doi.org/10.1016/j.ijsu.2016.08.117
1256: ACCURACY OF INFORMATION ON SURGICAL MANAGEMENT OF
BREAST CANCER ON THE INTERNET
R. Waqar*, A. Oomman, N. Kirmani. Princess Alexandra Hospital, Harlow,
Essex, UK.
Aim: The aim of this study was to assess the accuracy and accessibility of
the information on the Surgical Management of Breast Cancer on the
internet.
Method: The contents of the top 100 websites from three different search
engines were selected. The quality of websites was evaluated using an
investigator-designed appraisal tool based on the guidelines from NICE,
Association of Breast Surgery and Good Surgical Practice.
Result: Reassuringly in 90% of the websites Surgical procedures like
‘Mastectomy’, ‘Breast conserving surgery’, ‘lymph node surgery’ and
‘breast reconstruction’ were discussed.Only 29% websites discussed
“Management of contralateral breast”.
Particular areas of weakness were the lack of information on management
of post-operative complications, surveillance and management of the
contralateral breast.
Conclusion: There appears to be a great variability in the quality of in-
formation present online on the surgical management of Breast cancer.
Grading of websites according to the accuracy of information they contain
may also enable healthcare professionals to signpost patients to trust-
worthy, up-to-date websites. There is an onus of the Royal College of
Surgeons and Surgical Associations to ensure that they invest in websites
that provide accurate information on the Surgical management of Breast
Cancer, so that nursing patients receive high quality information.http://dx.doi.org/10.1016/j.ijsu.2016.08.118Cardiothoracic surgery
0127: BLEEDING COMPLICATIONS IN AORTIC SURGERY WITH OR
WITHOUT APROTININ
A. Curtis 1,*, C. Rajakaruna 2. 1University of Bristol, Bristol, UK; 2Bristol Heart
Institute, Bristol, UK.
Aprotinin (Trasylol) may reduce bleeding complications in aortic surgery
but the evidence is limited and conﬂicting. There is also evidence that
aprotinin increases renal failure, stroke and mortality.
Aim: To determine whether aprotinin reduces bleeding complications in
adults undergoing aortic surgery.
Method: A single centre retrospective cohort study including 281
consecutive adult patients undergoing aortic surgery at the Bristol HeartInstitute. Of these, 105 (37.4%) received aprotinin and 176 (62.6%) did not.
The primary outcome was bleeding complication consisting of (i) post-
operative blood loss; (ii) transfusion requirements and (iii) haemoglobin
reduction. Secondary outcomes included systemic complications. Statis-
tical analysis was completed using the Mann Whitney U Test and Chi-
squared Test.
Result: Baseline characteristics and perioperative variables were similar
between the two groups. Total blood loss was only marginally lower
(p > 0.05) in the aprotinin group (750mL vs. 762.5mL) which didn't cause a
signiﬁcant difference in percentage haemoglobin reduction following
surgery (28.6% vs. 29.7%). There was also a non-signiﬁcant reduction in
blood product transfusions in the aprotinin group (52.4% vs. 59.1%).
Conclusion: This is the largest study to explore aprotinin use in aortic
surgery. Our results don't support the use of aprotinin in aortic surgery
with no signiﬁcant reduction in bleeding complications.http://dx.doi.org/10.1016/j.ijsu.2016.08.120
0172: MUCH ADO ABOUT NOTHING e ARE PATIENTS AWARE OF THE
MORTALITY DATA PUBLISHED BY THE SOCIETY OF CARDIOTHORACIC
SURGEONS?
J. Choi 1,*, R. Boix 2, J. Roxburgh 2, M. Sabetai 2. 1King's College London,
London, UK; 2Department of Cardiac Surgery, Guy's and St Thomas' NHS
Foundation Trust, London, UK.
Objective: Surgeon-speciﬁc mortality data (SSMD) in cardiac surgery
appeared in the public domain in 2007. However, there is no clear indi-
cation that the public appreciates or engages with these data. Our aimwas
to assess patient awareness and interpretation of the Society of Cardio-
thoracic Surgeons (SCTS) data on SSMD and hospital-speciﬁc mortality
data (HSMD).
Method: A questionnaire consisting of 17 questions, including SSMD and
HSMD published from 2010 to 2013 by the SCTS, was interpreted by 42
cardiac patients, 4 days post-operatively.
Result: No patients were aware of the HSMD and only 7% (3/42) of the
patients were aware of the SSMD published on the SCTS website. 83% (35/
42) of patients interpreted the SSMD correctly. Although these data only
mattered to 38%(16/42) of patients, 50% (21/42) would appreciate a dis-
cussion about the mortality data, prior to their operation.
Conclusion: Our study showed very little patient awareness of the SCTS
data. However, themajority of patients were able to interpret themortality
data and there was willingness to engage - patients care about results.
Therefore we pose the question e is it worth the SCTS investing in
increasing patient awareness or should we be using this data solely for
monitoring purposes?http://dx.doi.org/10.1016/j.ijsu.2016.08.121
0295: AORTIC REGURGITATION INCREASES WITH DURATION
FOLLOWING HEARTWARE HVAD IMPLANTATION
V. Naruka 2,*, S. Tsui 1, S. Pettit 1, C. Lewis 1. 1 Papworth Hospital NHS
Foundation Trust, Cambridge, UK; 2University of Cambridge and Papworth
Hospital NHS Foundation Trust, Cambridge, UK.
Aim: Patient survival and performance of continuous-ﬂow left ventricular
assist devices (CF LVAD) are adversely affected by aortic regurgitation (AR).
We examined the development of AR during HeartWare HVAD support.
Method: We reviewed records of 56 consecutive patients after HVAD
implantation between 2009 and 2015. Aortic valve (AV) opening was
encouraged by optimisation of LVAD speed and use of the Lavare cycle in
all patients.
Result: At LVAD implant: 2 patients required bioprosthetic AV
replacement (AVR); 12 had mild AR. During LVAD support: 18 patients
had no AR or resolution of mild AR. De novo mild AR developed in 22
patients. Moderate AR developed in 13 (10 de novo, 3 from pre-LVAD
mild AR). Severe AR developed in 2 (1 de novo, 1 from pre-LVAD mild
AR), both underwent urgent transplantation. Kaplan-Meier survival
Abstracts / International Journal of Surgery 36 (2016) S31eS132 S55estimates for freedom from moderate or severe AR (censored for death/
heart transplant) were 85% (1 year), 71% (2 years) and 52% (3 and 4
years).
Conclusion: Increasing AR occurred during HVAD support despite avoid-
ance strategies. Concomitant bioprosthetic AVR should be considered at
implant if there is greater than mild AR and the expected duration of LVAD
support is long.http://dx.doi.org/10.1016/j.ijsu.2016.08.122
0461: COMPLIANCE WITH ANTICOAGULATION GUIDELINES FOLLOWING
HEART VALVE SURGERY: LESSONS FROM FOUR CYCLES OF AUDIT
A. Patel 1, N. Drury 1, J. McNamara 2,*, D. Pagano 1. 1Department of
Cardiothoracic Surgery, Queen Elizabeth Hospital., Birmingham, UK;
2University of Birmingham, Birmingham, UK.
Aim: Following heart valve surgery, patients often require long-term
treatment with anticoagulation therapy; local evidence-based guidelines
were developed for postoperative management. Several audit cycles have
been completed to assess and improve compliance with these guidelines.
Method: Data was retrospectively collected from the local PATS database
for the last consecutive 210 patients undergoing valve surgery. The stan-
dard was 100% compliance with the guidelines. Data from this audit cycle
was compared with the previous three cycles.
Result: First cycle (2009): 80% of patients were treated according to the
guidelines; recommended guidelines emphasised in the doctors' induc-
tion. Second cycle (2010): 90% according to the guidelines; recom-
mended incorporating a drop-down box into the electronic discharge
and displaying a guidelines poster in the doctors' ofﬁce. Third cycle
(2012): 81% according to the guidelines. Fourth cycle (2015): 69% ac-
cording to the guidelines. Adherence was lowest in patients who had
undergone mitral valve repair (36%) due to alternative use of antiplatelet
agents.
Conclusion: Previous audit cycle implementations improved compliance
with local guidelines but there is now signiﬁcant deviation. The use of
antiplatelet agents after mitral valve repair is now recommended in the
latest AHA/ACC guidance (2014) and differs from our current local guide-
lines which now require updating.http://dx.doi.org/10.1016/j.ijsu.2016.08.123
0486: A COMPARISON OF TRANSCATHETER AORTIC VALVE IMPLANTA-
TION AGAINST CONVENTIONAL THERAPIES IN THE TREATMENT OF SE-
VERE AORTIC STENOSIS IN RISK PATIENTS
A. Aftab. University of Nottingham, Nottingham, UK.
Aim: The present literature review aims to explore and compare the
application of transcatheter aortic valve replacement (TAVI) against con-
ventional therapies in the treatment of severe aortic stenosis (AS) in pa-
tients of varying operative risk.
Method: An electronic search was performed on 4 databases to identify
comparative studies on TAVI vs. conventional therapies. All-cause mor-
tality was the primary outcome. Procedural outcomes such as stroke,
vascular complications and major bleeding were determined as secondary
outcomes.
Result: 17 pertinent studies were included. TAVI signiﬁcantly reduced all-
cause mortality at all time points over follow-up compared with standard
therapy in inoperable patients, although it was associated with increased
vascular complications and stroke. All-cause mortality was comparable
between TAVI and surgical aortic valve replacement (SAVR) in high-risk
and lower than high-risk patients. Quality-of-life data demonstrated the
superiority of TAVI over standard therapy in inoperable patients; it showed
no signiﬁcant difference between TAVI and SAVR.
Conclusion: For the treatment of severe AS, TAVI may be recognised as an
effective alternative to standard therapy for inoperable patients. TAVI hasalso established itself as an effective intervention in high-risk and lower
than high-risk patients with outcomes comparable with SAVR.http://dx.doi.org/10.1016/j.ijsu.2016.08.124
0495: APROTININ FOR REDUCTION OF POST-OPERATIVE BLOOD LOSS
AND INCIDENCES OF CEREBROVASCULAR EVENTS FOLLOWING ENDO-
CARDITIS SURGERY. A PILOT STUDY
R. Karsan*, C. Rajakaruna. University of Bristol, Bristol, UK.
Aprotinin has shown to be efﬁcacious in cardiac surgeries involving high
blood loss. There is strong evidence indicating it effectively reduces post-
operative blood loss and the need for blood transfusion following surgery.
Evidence is however, limited in relation to the potential beneﬁts/risks of
aprotinin in open-heart endocarditis surgery.
Aim: To determine whether aprotinin reduces post-operative bleeding
following endocarditis surgery, compared to conventional techniques.
Method: In this retrospective study, data from 50 patients who underwent
endocarditis surgery from 2011-15, was analysed comparing 24-hour post-
operative blood loss, kidney function and cerebrovascular events. Com-
parisons of aprotinin vs. control (tranexamic acid) were undertaken with;
paired t-test, Mann-Whitney U test, Kruskal-Wallis test and Chi-squared
analysis.
Result: Blood loss over 24 hours was found to be lower in the group given
aprotinin, with a signiﬁcant difference seen at 6 and 12 hours post-
operatively (p¼0.03). The need for blood transfusion was also seen to be
lower in the aprotinin arm (RR ¼ 0.875, 95% CI ¼ 0.55-1.38 p ¼ 0.09).
Conclusion: This pilot study highlights potential beneﬁts of aprotinin to
reduce post-operative blood loss and transfusion requirement in endo-
carditis surgery, This is only a snapshot but suggests that the study
methodology employed is viable to a much larger study with increased
power.http://dx.doi.org/10.1016/j.ijsu.2016.08.125
0834: CLINICAL CASE FOCUSING ON CARDIAC IMAGING AND TUMOUR
CHARACTERISATION OF A CARDIAC PAPILLARY FIBROELASTOMA
C. Rees*, A. Brazier, F. Sogliani. Manchester Royal Inﬁrmary, Manchester, UK.
Background: Cardiac papillary ﬁbroelastoma (CPF) is a rare cardiac
tumour. Although non-malignant, these tumours can cause signiﬁcant
morbidity and even death through embolization andmass effects. Previous
meta-analysis has advocated surgical intervention in those with highly
mobile or symptomatic tumours. Assessing mobility of cardiac structures
requires clear and accurate imaging, of which multiple modes are avail-
able. This paper presents a case of CPF with a focus on cardiac imaging and
tumour characterization.
Case: A 74 year old gentlemanwas referred by his general practitioner for a
transthoracic echogardiogram because of severe hypertension. This
revealed a 1cm mass in the left ventricle. Further imaging was performed
including transoesophageal echocardiogram and cardiac magnetic reso-
nance imaging. This characterised the mass as a highly mobile CPF. Despite
the lack of symptoms that could be attributed to the tumour, it was excised
on the grounds of high thromboembolic risk. This was done on an elective
outpatient basis and he made a straightforward recovery.
Discussion: Primary cardiac tumours have an incidence of approximately
0.02%. Unlike the more common cardiac myxoma, the case for surgical
resection of CPF is less clear cut. In our case the decision to excise the
tumour was made on the grounds of tumour mobility.http://dx.doi.org/10.1016/j.ijsu.2016.08.126
